InfiCure Bio will be presenting at the LSX Nordic Congress in Stockholm on August 28th. The company will be presenting during the start up showcase as one of the growth stage private companies.

InfiCure Bio has received additional funding from NLC InfiCure Bio and Partnerinvest Övre Norrland to speed up the validation of additional indications in the NIF mouse. This is a golden opportunity to broaden our customer base and increase the revenue of the company.